Developers of a domestic vaccine against coronavirus received impressive funding – this guarantees the first stage of human trials
Rokote Laboratories Finland Oy received € 9 million to develop a Finnish coronavirus nasal spray vaccine. The investment ensures that the first and second phase of human trials of the vaccine are carried out.
Developers of the Finnish covid vaccine have received impressive funding for further research.
Rokote Laboratories Finland Oy has received € 9 million to develop a nasal spray vaccine.
Business Finland, a local business development organization, has allocated 5.5 million euros to vaccine developers for clinical trials of the vaccine. An additional € 3.5 million was received from the Jenny Foundation and Antti Vihuri , the Finnish Cultural Foundation and Ferring Ventures SA.
– With the funds received, we can start manufacture of the FINCoVac vaccine and conduct human trials, states Pasi Kemppainen of Rokote Laboratories Oy.
The funded vaccine was developed based on research conducted jointly by the University of Helsinki and the University of Eastern Finland.